LeMaitre Vascular (NASDAQ:LMAT) Updates Q4 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its fourth quarter earnings guidance on Thursday. The company provided EPS guidance of $0.47 to $0.51 for the period, compared to the consensus EPS estimate of $0.46. The company issued revenue guidance of $54.9 million to $56.9 million, compared to the consensus revenue estimate of $55.49 million. LeMaitre Vascular also updated its FY 2024 guidance to 1.910-1.960 EPS.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded up $6.49 during mid-day trading on Friday, hitting $94.88. The stock had a trading volume of 343,645 shares, compared to its average volume of 105,134. The business has a 50 day moving average price of $89.59 and a two-hundred day moving average price of $83.25. LeMaitre Vascular has a 1 year low of $45.96 and a 1 year high of $101.67. The firm has a market cap of $2.13 billion, a P/E ratio of 51.85, a price-to-earnings-growth ratio of 2.32 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.39% and a net margin of 19.40%. The company had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the previous year, the business earned $0.33 EPS. LeMaitre Vascular’s revenue was up 15.6% compared to the same quarter last year. Equities research analysts predict that LeMaitre Vascular will post 1.86 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.67%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LMAT shares. JMP Securities increased their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective on the stock. Barrington Research increased their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

Insider Buying and Selling

In other news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 10.79% of the stock is currently owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.